Logo-ipp
Submitted: 20 May 2020
Accepted: 14 Jun 2020
ePublished: 20 Jun 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. 2021;7(1): e03.
doi: 10.34172/ipp.2021.03
  Abstract View: 65
  PDF Download: 43

Review

Sphingosine 1 phosphate agonists (SPI); a potential agent to prevent acute lung injury in COVID-19

Sepideh Zununi Vahed 1 ORCID logo, Shahram Ghiyasvand 1, Seyed Mahdi Hosseiniyan Khatibi 1 ORCID logo, Bhargav Patel 2 ORCID logo, Mohammadali Mohajel Shoja 3, Ramin Tolouian 4 ORCID logo, Mohammadreza Ardalan 1 ORCID logo

1 Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Department of Internal Medicine, University of Arizona, Tucson, AZ, USA
3 Department of Surgery, University of Illinois at Chicago-Metropolitan Group Hospitals (UIC-MGH), Chicago, Illinois, USA
4 Division of Nephrology, College of Medicine, University of Arizona, Tucson, AZ, USA

Abstract

SARS-CoV-2 is a worldwide pandemic, that has led to the morbidity and mortality of millions of people. This virus rapidly proliferates and destroys lung epithelial cells directly, which is worsened by a subsequent cytokine storm. This cytokine storm diffusely damages the alveolar barriers and leads to fibrin and fluid exudation, hyaline membrane formation, and infiltration of inflammatory cells into the lung causing acute respiratory distress syndrome (ARDS). To date, there exists no medication to treat SARS-CoV-2 infection and novel new therapeutics are still being explored to prevent or limit the damage to the lung. Sphingosine 1-phosphate (S1P) is an effective bioactive lipid mediator and its related signaling pathways are vital for endothelial cell integrity. Stabilizing the pulmonary endothelial barrier and decreasing the inflammatory infiltrate by S1P analogs such as Fingolimod (FTY720-P) would be a new therapeutic approach for the hindrance of pulmonary exudation and subsequent ARDS.
Keywords: Cytokine storm, COVID-19, SARS-CoV-2, Fingolimod, FTY720-P, Acute respiratory distress syndrome
Citation: Zununi Vahed S, Ghiyasvand S, Hosseiniyan Khatibi SM, Patel B, Mohajel Shoja M, Tolouian R, et al. Sphingosine 1 phosphate agonists (SPI); a potential agent to prevent acute lung injury in COVID-19. Immunopathol Persa. 2021;7(1):e03. DOI:10.34172/ ipp.2021.03.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 65

Your browser does not support the canvas element.


PDF Download: 43

Your browser does not support the canvas element.